Gracell Competitors

Delisted . USA . 
Stock . Gracell Biotechnologies
GRCLDelisted Stock  USD 4.02  0.26  6.07%   
Gracell Biotechnologies competes with Monte Rosa, Design Therapeutics, Erasca, NextCure, and CytomX Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Gracell Biotechnologies competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Gracell Biotechnologies to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Gracell Biotechnologies competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Gracell Biotechnologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
4.024.024.02
Details
Intrinsic
Valuation
LowRealHigh
3.323.324.42
Details
Naive
Forecast
LowNextHigh
4.624.624.62
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.934.515.09
Details

Gracell Biotechnologies Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Gracell Biotechnologies and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Gracell and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Gracell Biotechnologies does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
TERN
+ 0.82
CTMX
CTMX
+ 0.75
THRX
SPRO
+ 0.71
THRX
SPRO
+ 0.67
CTMX
TERN
+ 0.65
THRX
TERN
+ 0.62
NLTX
  
High negative correlations   
CTMX
- 0.66
GLUE
TERN
- 0.44
GLUE
CTMX
- 0.35
DSGN
GLUE
- 0.28
THRX
NXTC
- 0.24
GLUE
NXTC
- 0.18
DSGN

Risk-Adjusted Indicators

There is a big difference between Gracell Stock performing well and Gracell Biotechnologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Gracell Biotechnologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
THRX  5.44 (0.69) 0.00 (0.49) 0.00 
 0.00 
 11.75 
(8.57)
 90.33 
GLUE  5.33  0.74  0.22  0.34  3.86 
(7.30)
 10.11 
(8.18)
 102.66 
DSGN  4.07  0.07  0.04  0.15  5.31 
(4.43)
 9.61 
(8.21)
 35.31 
ERAS  3.29 (0.18)(0.02) 0.02  3.67 
(3.81)
 7.34 
(5.38)
 17.38 
NXTC  2.59 (0.35) 0.00  2.11  0.00 
 0.00 
 5.22 
(6.37)
 21.68 
CTMX  2.58 (0.53) 0.00 (0.35) 0.00 
 0.00 
 5.00 
(5.22)
 20.61 
NLTX  2.25 (0.22) 0.00 (0.55) 0.00 
 0.00 
 4.05 
(3.53)
 27.84 
SPRO  1.78 (0.27) 0.00 (0.41) 0.00 
 0.00 
 3.79 
(4.58)
 14.92 
ASMB  2.91  0.09  0.00  0.31  4.46 
(2.82)
 8.49 
(5.34)
 24.80 
TERN  3.37 (0.50) 0.00 (0.29) 0.00 
 0.00 
 5.68 
(5.96)
 34.09 
All Fundamental Data

Gracell Biotechnologies Competitive Analysis

The better you understand Gracell Biotechnologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Gracell Biotechnologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Gracell Biotechnologies' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GRCL THRX GLUE DSGN ERAS NXTC CTMX NLTX SPRO ASMB
 6.07 
 4.02 
Gracell
 3.92 
 3.71 
Theseus
 0.35 
 8.46 
Monte
 0.90 
 5.62 
Design
 2.22 
 2.76 
Erasca
 0.84 
 1.20 
NextCure
 7.87 
 0.96 
CytomX
 1.43 
 0.69 
Neoleukin
 0.86 
 1.15 
Spero
 1.53 
 14.81 
Assembly
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Unstable
Moderately volatile
Relatively risky
Very risky
Dangerous
Very steady
Relatively risky
Relatively risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Modest
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Below Average
Low
Below Average
Average
Above Average
Dangerous
Very Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Strong Buy
Buy
Strong Buy
Buy
Buy
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Current Ratio
8.01
27.54
20.11
48.96
17.09
33.87
2.05
12.78
3.65
8.31
Net Asset
1.66 B
222.45 M
303.75 M
289.64 M
395.3 M
128.04 M
201.79 M
115.95 M
182.39 M
137.47 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
0.11
N/A
0.15
-2.12
EBITDA
(509.64 M)
(66.44 M)
(137.09 M)
(66.33 M)
(121.31 M)
(59.04 M)
(4.31 M)
(56.48 M)
27.15 M
(64.2 M)
Current Valuation
3.32 B
(20.19 M)
323.11 M
66.66 M
497.39 M
(36.59 M)
(37.34 M)
(35.02 M)
(8.43 M)
2.09 M
Price To Book
4.39
0.81
2.54
1.26
1.7
0.44
5.04
0.44
0.97
3.68
Operating Margin
N/A
N/A
-2.88
N/A
N/A
N/A
0.12
N/A
-1.87
-1.43
Retained Earnings
(1.63 B)
(112.19 M)
(365.89 M)
(177.63 M)
(606.01 M)
(324.48 M)
(723.45 M)
(451.06 M)
(391.07 M)
(785.75 M)
Current Asset
N/A
223.75 M
N/A
N/A
N/A
46.99 M
189.75 M
289 K
7.3 M
68.37 M
Beta
-0.34
3.98
1.3
1.83
1.16
0.79
1.06
1.1
0.63
0.59
Number Of Employees
314
38
133
54
126
82
120
7
46
65
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
96.57 M
44.65 M
61.44 M
56.62 M
282.73 M
28.01 M
78.26 M
2.35 M
54.52 M
6.36 M
Cash Flow From Operations
(482.65 M)
(49.63 M)
(43.8 M)
(58.56 M)
(101.22 M)
(52.97 M)
(56.03 M)
(45.61 M)
(32.99 M)
22.74 M
Total Debt
182.98 M
3.98 M
46.04 M
3.05 M
55.86 M
6.61 M
13.97 M
12.07 M
5.54 M
2.34 M
Return On Equity
-0.32
-0.26
-0.61
-0.18
-0.39
-0.55
-54.75
-0.38
0.26
-1.02
Z Score
1.78
26.67
N/A
N/A
N/A
N/A
N/A
-5.73
N/A
N/A
Return On Asset
-0.19
-0.18
-0.28
-0.14
-0.19
-0.31
0.0233
-0.19
0.1
-0.35
Number Of Shares Shorted
1.19 M
401.68 K
7.84 M
2.59 M
32.97 M
66.12 K
5.67 M
26.4 K
625.19 K
7.95 K
Book Value Per Share
16.9
5.17
3.35
4.46
1.65
4.1
-0.3
34.18
2.02
7.5
Current Liabilities
N/A
11.28 M
N/A
N/A
N/A
5.53 M
15.74 M
1.02 M
6.04 M
3.4 M
Total Asset
1.66 B
222.45 M
303.75 M
289.64 M
395.3 M
128.04 M
201.79 M
115.95 M
182.39 M
137.47 M
Debt To Equity
0.11
0.018
0.16
0.011
0.07
0.01
0.67
0.11
0.19
0.041
Short Ratio
0.87
0.82
1.65
16.31
23.89
1.89
9.58
1.7
2.08
0.41
Target Price
10.58
5.25
16.43
7.0
5.75
3.33
5.29
1.5
5.0
35.5
Shares Owned By Institutions
63.11
93.28
90.66
56.9
86.99
57.5
65.31
45.58
23.04
18.79
Market Capitalization
989.87 M
181.28 M
521.6 M
318.21 M
763.36 M
33.33 M
69.65 M
8.2 M
63.24 M
95.6 M
Price To Earning
N/A
737.67
1.91
N/A
N/A
-25.44
-11.41
-4.6
81.2
-10.58
Price To Earnings To Growth
N/A
N/A
N/A
N/A
0.37
0.03
-1.8
-0.03
N/A
N/A
Price To Sales
732.21
N/A
34.83
22642.01
N/A
9.52
0.55
N/A
0.53
4.45
Net Income
(496.98 M)
(56.61 M)
(135.35 M)
(66.86 M)
(125.04 M)
(62.72 M)
(569 K)
(57.56 M)
22.81 M
(61.23 M)
Earnings Per Share
-0.97
-1.34
-1.78
-0.85
-0.79
-2.1
0.16
-12.28
0.08
-6.89
Shares Owned By Insiders
16.39
2.55
0.7
36.45
12.39
8.85
1.0
16.46
20.13
31.62
Revenue
N/A
N/A
N/A
N/A
N/A
N/A
101.21 M
N/A
96.73 M
7.16 M
Working Capital
1.28 B
190.99 M
189.62 M
274.96 M
294.52 M
105.84 M
27.02 M
88.07 M
94.06 M
94.56 M
Cash And Equivalents
1.71 B
212.43 M
294.14 M
359.38 M
371.48 M
185.49 M
194.29 M
116.46 M
45.4 M
116.69 M
Cash Per Share
25.28
5.55
6.32
6.45
3.04
6.68
2.94
2.73
1.29
2.41
Gross Profit
366 K
N/A
N/A
(48.61 M)
N/A
(54.2 M)
53.16 M
N/A
(42.11 M)
(63.9 M)
Day Typical Price
4.07
3.7
8.62
5.63
2.77
1.21
0.95
0.69
1.14
15.03
Accumulation Distribution
0.0888
0.0904
57840.28
0.0569
101571.0
822.02
155177.0
0.0563
18082.32
2474.56
Market Facilitation Index
0.38
0.35
0.0
0.33
N/A
0.0
N/A
0.04
N/A
0.0
Daily Balance Of Power
(0.68)
0.4
(0.05)
0.1515
0.375
0.3333
0.6364
(0.25)
(0.14)
(0.25)
Period Momentum Indicator
(0.26)
0.14
(0.03)
0.05
0.06
0.01
0.07
(0.01)
(0.01)
(0.23)
Rate Of Daily Change
0.94
1.04
1.0
1.01
1.02
1.01
1.08
0.99
0.99
0.98
Day Median Price
4.09
3.7
8.71
5.64
2.78
1.21
0.95
0.69
1.14
15.15
Price Action Indicator
(0.20)
0.085
(0.26)
0.01
0.01
(0.01)
0.05
(0.01)
0.01
(0.45)
Relative Strength Index
58.18
53.21
75.15
58.35
64.3
43.8
37.93
62.4
54.48
56.68
Coefficient Of Variation
584.38
(1,975)
1086.43
1554.97
7032.28
(989.92)
(904.17)
(2,179)
(1,252)
2742.42
Mean Deviation
5.71
5.44
5.33
4.07
3.29
2.59
2.58
2.25
1.78
2.91
Jensen Alpha
1.25
(0.69)
0.7387
0.0666
(0.18)
(0.35)
(0.53)
(0.22)
(0.27)
0.0862
Total Risk Alpha
0.104
(2.24)
(0.83)
(0.54)
(0.59)
(0.94)
(0.93)
(0.76)
(0.60)
(0.51)
Sortino Ratio
0.1801
N/A
0.2225
0.0399
(0.02)
N/A
N/A
N/A
N/A
0.0047
Downside Variance
52.09
N/A
21.11
34.7
15.69
N/A
N/A
N/A
N/A
20.74
Standard Deviation
8.36
10.73
12.53
5.69
4.02
3.61
3.45
3.7
2.49
4.17
Kurtosis
2.99
30.61
47.52
2.01
(0.47)
2.71
1.91
13.95
2.55
3.52
Potential Upside
16.34
11.75
10.11
9.61
7.34
5.22
5.0
4.05
3.79
8.49
Treynor Ratio
1.02
(0.49)
0.3413
0.1486
0.0247
2.11
(0.35)
(0.55)
(0.41)
0.3073
Maximum Drawdown
52.11
90.33
102.66
35.31
17.38
21.68
20.61
27.84
14.92
24.8
Variance
69.86
115.1
156.97
32.39
16.17
13.05
11.88
13.69
6.22
17.38
Market Risk Adjusted Performance
1.03
(0.48)
0.3513
0.1586
0.0347
2.12
(0.34)
(0.54)
(0.40)
0.3173
Risk Adjusted Performance
0.1403
(0.03)
0.08
0.058
0.019
(0.07)
(0.08)
(0.03)
(0.05)
0.0361
Skewness
0.4969
(4.49)
6.4
(0.19)
0.1148
0.6704
0.6992
(2.77)
0.7821
(0.55)
Semi Deviation
6.35
N/A
3.86
5.31
3.67
N/A
N/A
N/A
N/A
4.46
Information Ratio
0.1555
(0.06)
0.0816
0.0413
(0.02)
(0.14)
(0.15)
(0.08)
(0.13)
0.0051
Value At Risk
(6.25)
(8.57)
(8.18)
(8.21)
(5.38)
(6.37)
(5.22)
(3.53)
(4.58)
(5.34)
Expected Short fall
(6.70)
N/A
(7.30)
(4.43)
(3.81)
N/A
N/A
N/A
N/A
(2.82)
Downside Deviation
7.22
N/A
4.59
5.89
3.96
N/A
N/A
N/A
N/A
4.55
Semi Variance
40.27
N/A
14.87
28.21
13.45
N/A
N/A
N/A
N/A
19.87

Gracell Biotechnologies Competition Performance Charts

Five steps to successful analysis of Gracell Biotechnologies Competition

Gracell Biotechnologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Gracell Biotechnologies in relation to its competition. Gracell Biotechnologies' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Gracell Biotechnologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Gracell Biotechnologies' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Gracell Biotechnologies, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Gracell Biotechnologies position

In addition to having Gracell Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Machinery Thematic Idea Now

Machinery
Machinery Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Machinery theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Machinery Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Consideration for investing in Gracell Stock

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY